Cargando…
Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory proce...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766614/ https://www.ncbi.nlm.nih.gov/pubmed/24058910 http://dx.doi.org/10.1155/2013/607137 |
_version_ | 1782477298136514560 |
---|---|
author | Yanagida, Mitsuaki Kawasaki, Mikiko Fujishiro, Maki Miura, Masako Ikeda, Keigo Nozawa, Kazuhisa Kaneko, Hiroshi Morimoto, Shinji Takasaki, Yoshinari Ogawa, Hideoki Takamori, Kenji Sekigawa, Iwao |
author_facet | Yanagida, Mitsuaki Kawasaki, Mikiko Fujishiro, Maki Miura, Masako Ikeda, Keigo Nozawa, Kazuhisa Kaneko, Hiroshi Morimoto, Shinji Takasaki, Yoshinari Ogawa, Hideoki Takamori, Kenji Sekigawa, Iwao |
author_sort | Yanagida, Mitsuaki |
collection | PubMed |
description | Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory processes in RA patients. In order to identify novel disease-related proteins and candidate biomarkers, we analyzed the changes in the serum proteome profiles of patients with RA who were treated with tocilizumab. Serum samples were collected from the RA patients before and after tocilizumab treatment. Following immunodepletion of major proteins, the proteins were digested and labeled with isobaric tag, iTRAQ reagent. The proteins were identified and quantified using liquid chromatography-tandem mass spectrometry. Among a total of 311 proteins identified, seven were decreased and 16 were increased by tocilizumab treatment. Although some of the proteins are known to be related to RA, several are currently unknown with respect to their relationship to RA and may be involved in the development of this disease. This study is the first to perform a comparative serum proteomic analysis of RA patients treated with tocilizumab. Our results may contribute to the identification of novel disease-related proteins and enhance the understanding of the pathogenesis of RA. |
format | Online Article Text |
id | pubmed-3766614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37666142013-09-22 Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody Yanagida, Mitsuaki Kawasaki, Mikiko Fujishiro, Maki Miura, Masako Ikeda, Keigo Nozawa, Kazuhisa Kaneko, Hiroshi Morimoto, Shinji Takasaki, Yoshinari Ogawa, Hideoki Takamori, Kenji Sekigawa, Iwao Biomed Res Int Clinical Study Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory processes in RA patients. In order to identify novel disease-related proteins and candidate biomarkers, we analyzed the changes in the serum proteome profiles of patients with RA who were treated with tocilizumab. Serum samples were collected from the RA patients before and after tocilizumab treatment. Following immunodepletion of major proteins, the proteins were digested and labeled with isobaric tag, iTRAQ reagent. The proteins were identified and quantified using liquid chromatography-tandem mass spectrometry. Among a total of 311 proteins identified, seven were decreased and 16 were increased by tocilizumab treatment. Although some of the proteins are known to be related to RA, several are currently unknown with respect to their relationship to RA and may be involved in the development of this disease. This study is the first to perform a comparative serum proteomic analysis of RA patients treated with tocilizumab. Our results may contribute to the identification of novel disease-related proteins and enhance the understanding of the pathogenesis of RA. Hindawi Publishing Corporation 2013 2013-08-22 /pmc/articles/PMC3766614/ /pubmed/24058910 http://dx.doi.org/10.1155/2013/607137 Text en Copyright © 2013 Mitsuaki Yanagida et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Yanagida, Mitsuaki Kawasaki, Mikiko Fujishiro, Maki Miura, Masako Ikeda, Keigo Nozawa, Kazuhisa Kaneko, Hiroshi Morimoto, Shinji Takasaki, Yoshinari Ogawa, Hideoki Takamori, Kenji Sekigawa, Iwao Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody |
title | Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody |
title_full | Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody |
title_fullStr | Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody |
title_full_unstemmed | Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody |
title_short | Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody |
title_sort | serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibody |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766614/ https://www.ncbi.nlm.nih.gov/pubmed/24058910 http://dx.doi.org/10.1155/2013/607137 |
work_keys_str_mv | AT yanagidamitsuaki serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT kawasakimikiko serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT fujishiromaki serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT miuramasako serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT ikedakeigo serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT nozawakazuhisa serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT kanekohiroshi serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT morimotoshinji serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT takasakiyoshinari serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT ogawahideoki serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT takamorikenji serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody AT sekigawaiwao serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody |